Recognizing Altitude Sickness: AMS, HACE, and HAPE Symptoms Every Athlete Should Know

Altitude sickness doesn't care how fit you are. Elite marathoners, seasoned mountaineers, and weekend warriors all face the same physiological reality: ascend too fast, and your body's oxygen-delivery systems fall behind. Recognizing the symptoms of altitude sickness — and knowing the difference between acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE) — is not optional knowledge for athletes training above 2,500 m (8,200 ft). It is a clinical skill that can prevent serious harm.

This guide breaks down the full spectrum from mild AMS to life-threatening HACE and HAPE, explains the underlying physiology, and gives you the decision frameworks you need on the mountain.

Why Altitude Makes You Sick

At sea level, the partial pressure of oxygen (PO₂) in inspired air is approximately 150 mmHg. At 3,000 m (9,840 ft), it drops to around 107 mmHg — a roughly 30% reduction. At 4,500 m (14,760 ft), you're breathing air with less than half the oxygen density you'd find at the coast.

The body responds with a cascade of compensatory mechanisms: increased ventilation (hypoxic ventilatory response), elevated heart rate, and — over days — a surge in erythropoietin (EPO) to stimulate red blood cell production. These adaptations are the upside of altitude exposure. Altitude sickness is the downside — what happens when the rate of ascent exceeds the rate of adaptation.

The primary driver of altitude illness is hypobaric hypoxia combined with insufficient acclimatization time. Genetic variability in the hypoxic inducible factor (HIF) pathway, prior altitude experience, and pre-ascent fitness level all modulate individual risk, but no profile is immune.

Acute Mountain Sickness (AMS): The Warning Sign

AMS is the mildest and most common form of altitude illness. It typically presents within 6–12 hours of arrival at altitude and resolves with rest or descent over 12–48 hours.

AMS Symptoms

The Lake Louise Scoring System (LLSS) — the clinical standard used in most research — defines AMS around five core symptoms, each rated 0–3:

Diagnosis: A headache plus at least one other symptom, occurring in the context of a recent ascent, meets the threshold for AMS diagnosis. You do not need all five.

Physiology of AMS

AMS is driven largely by a mild, transient cerebral vasodilation in response to hypoxia. The brain's autoregulatory system maintains perfusion pressure, but this comes at a cost: mild intracranial pressure increases. Simultaneously, hypoxia-driven fluid shifts increase extracellular volume in brain tissue. The headache is partly vascular, partly pressure-mediated.

Increased sympathetic tone also contributes to GI stasis (explaining nausea) and elevated heart rate at rest — which athletes often misinterpret as cardiac fitness regression.

AMS Decision Framework

• Mild AMS (LLSS 3–5): Rest at current altitude. Do not ascend further. NSAIDs (ibuprofen 600 mg) or acetaminophen manage headache. Maintain hydration. Monitor over 12–24 hours.
• Moderate AMS (LLSS 6–9) or worsening: Descend at minimum 300–500 m. Acetazolamide (Diamox) 250 mg twice daily accelerates acclimatization and reduces symptom severity — use under medical supervision.
• Severe AMS or worsening: Descend immediately. This is the one unambiguous rule: if symptoms worsen, go down.

High-Altitude Cerebral Edema (HACE): AMS Gone Critical

HACE is severe AMS that has progressed to frank brain swelling. It is less common than AMS but carries significant mortality risk if not recognized and treated rapidly. Most cases develop at altitudes above 4,000 m (13,100 ft), though documented cases exist at lower elevations in susceptible individuals.

HACE Symptoms

The clinical progression from AMS to HACE typically follows this sequence:

1. Worsening headache that does not respond to analgesics
2. Profound fatigue — the person becomes lethargic, wants only to lie down
3. Ataxia — the pathognomonic sign: inability to walk heel-to-toe in a straight line ("tandem gait test"). This single finding should prompt immediate descent.
4. Altered consciousness: confusion, disorientation, behavioral changes, uncharacteristic irritability
5. In advanced cases: stupor, seizure, coma

Field test: Ask the person to walk a straight line, heel-to-toe, for 10 steps. If they cannot, treat it as HACE.

Physiology of HACE

HACE represents a failure of cerebral blood-brain barrier integrity under sustained hypoxia. Hypoxia upregulates vascular endothelial growth factor (VEGF) and disrupts tight junction proteins, allowing fluid and plasma proteins to leak into brain parenchyma. The resulting cytotoxic and vasogenic edema increases intracranial pressure to dangerous levels.

MRI studies of HACE patients show T2 signal changes in the corpus callosum and splenium — regions sensitive to osmotic stress — confirming the edematous pathology that distinguishes HACE from simple AMS.

HACE Treatment Protocol

1. Descend immediately — this is the only definitive treatment. Even 300 m can produce dramatic improvement.
2. Dexamethasone 8 mg immediately (IM, IV, or oral), then 4 mg every 6 hours. Dexamethasone reduces cerebral vasogenic edema through anti-inflammatory mechanisms. It is a bridge, not a cure — descent is mandatory.
3. Supplemental oxygen (2–4 L/min) if available.
4. Gamow bag / portable hyperbaric chamber if descent is impossible (e.g., weather hold). These devices temporarily simulate lower altitude by pressurizing the patient's environment. Treatment duration: 1–2 hours.

Do not wait for symptoms to "see if they improve on their own" when ataxia or altered consciousness is present.

High-Altitude Pulmonary Edema (HAPE): The Silent Killer

HAPE is the leading cause of death among altitude illnesses. It is more dangerous than HACE in many settings because its early symptoms are easily misattributed to normal fatigue or AMS, and because it can progress from mild symptoms to death within hours.

HAPE can occur with or without preceding AMS. Physically fit athletes are not protected — in fact, fit individuals may ascend faster, paradoxically increasing risk.

HAPE Symptoms

Early HAPE (days 2–4 after ascent):

• Dry cough — often dismissed as the "altitude cough" that is common above 3,500 m
• Reduced exercise tolerance beyond what acclimatization would predict
• Increased breathlessness on exertion
• Mild crackles (rales) audible with a stethoscope in the bases of both lungs

Progressive HAPE:

• Breathlessness at rest
• Cough productive of pink, frothy sputum (blood-tinged fluid from the flooded alveoli)
• Central cyanosis — bluish discoloration of lips and fingernails indicating severe hypoxemia
• SpO₂ values dramatically lower than expected for altitude (e.g., SpO₂ 65–75% at 4,000 m when acclimatized individuals typically read 80–88%)
• Extreme fatigue, inability to move without severe dyspnea

The HAPE Diagnostic Rule: Any athlete with dry cough + unusual dyspnea + low SpO₂ at altitude should be presumed to have early HAPE until proven otherwise.

Physiology of HAPE

HAPE is not cardiac — it is a form of non-cardiogenic pulmonary edema driven by exaggerated hypoxic pulmonary vasoconstriction (HPV). In hypoxia, pulmonary arteries constrict to shunt blood away from poorly ventilated alveoli — an adaptive mechanism in localized hypoxia. But at high altitude, where all alveoli are equally hypoxic, HPV is global and maladaptive.

The resulting over-perfusion of open pulmonary vessels under high pressure damages the capillary-alveolar membrane (capillary stress failure), flooding alveolar spaces with protein-rich fluid and red blood cells. Gas exchange collapses, creating a vicious cycle of worsening hypoxemia, further HPV, and greater edema.

Individuals with exaggerated HPV response (identified by high pulmonary artery pressure on exertion) are known to be HAPE-susceptible and have significantly higher rates of recurrence.

HAPE Treatment Protocol

1. Descend immediately — even 300–1,000 m dramatically reduces pulmonary artery pressure and fluid efflux.
2. Supplemental oxygen (4–6 L/min) — the single most effective pharmacological intervention. Oxygen directly reduces HPV. Target SpO₂ > 90%.
3. Nifedipine 30 mg extended-release (or 10 mg immediate-release) — a calcium channel blocker that reduces pulmonary artery pressure. Used when oxygen or descent is unavailable. Standard pre-treatment for HAPE-susceptible individuals.
4. Phosphodiesterase-5 inhibitors (sildenafil 50 mg, tadalafil 10 mg) — alternative to nifedipine, also reduce pulmonary vascular resistance.
5. Gamow bag — effective, buys time, but does not replace descent.
6. Salmeterol (inhaled) at 125 mcg twice daily has shown prophylactic benefit in HAPE-susceptible individuals by upregulating alveolar sodium transport.

Do not administer dexamethasone for HAPE unless co-existing HACE is suspected — it has no role in HAPE management.

Monitoring Tools: SpO₂ as an Early Warning System

Athletes spending time at altitude should carry a pulse oximeter. While SpO₂ alone doesn't diagnose altitude sickness, significant SpO₂ drops from your individual baseline can precede symptoms by hours.

Interpretation benchmarks (approximate):

• At 2,500 m: SpO₂ typically 92–96%
• At 3,500 m: SpO₂ typically 88–92% (acclimatized)
• At 4,500 m: SpO₂ typically 82–88% (acclimatized)

If your SpO₂ is 5–8% below these ranges, or trending downward over hours despite rest, treat it as a warning sign and reassess ascent plans.

Altitude Sickness Risk Factors for Athletes

Counterintuitively, VO₂ max and cardiorespiratory fitness do not predict AMS risk. Fit athletes often ascend faster, which increases risk. Genetics (HIF-1α polymorphisms, HPV magnitude) play a larger role than fitness in altitude illness susceptibility.

The Golden Rule of Altitude Illness

"If in doubt, go down."

Every major wilderness medicine organization — the Wilderness Medical Society (WMS), the International Society for Mountain Medicine (ISMM), and UIAA MedCom — converges on this principle. Symptoms that worsen, ataxia, altered mental status, or severe dyspnea at rest require descent. No training block, race preparation, or summit objective is worth HACE or HAPE.

Plan your ascent with built-in rest days. Follow the "climb high, sleep low" principle above 3,000 m. Know the Lake Louise Score. Carry a pulse oximeter. And never let ego override physiology.

Key Takeaways

• AMS is the mildest form — headache plus one other symptom. Treat with rest, analgesics, and halt ascent. If worsening, descend.
• HACE is severe brain swelling. Ataxia or altered consciousness = descend immediately + dexamethasone.
• HAPE is fluid in the lungs and the most lethal altitude illness. Dry cough + dyspnea + low SpO₂ = descend + oxygen + nifedipine.
• SpO₂ monitoring provides early warning — track trends, not just snapshots.
• Fitness does not protect you. Fast ascent rates and genetic susceptibility matter more than VO₂ max.

Track Your Altitude Acclimatization

Want to track your SpO₂ trends during altitude camps? Our Altitude Performance Calculator helps you interpret your readings and plan safe ascent profiles. Subscribe to our newsletter for weekly altitude physiology deep-dives delivered to serious athletes and coaches.